
Progyny (PGNY) Stock Forecast & Price Target
Progyny (PGNY) Analyst Ratings
Bulls say
Progyny is a leading fertility benefits management company with a stable business and a high retention rate among its clients. The company's relationships with clients are managed closely, and it is actively working to expand and retain them. While the reduction in expected covered lives may cause investor concerns, the company's guidance appears conservative and reflects past patterns when excluding the impact of Amazon's transition of services. The company's valuation is compelling, but further proof points of the 2026 selling season may be needed to alleviate investor fears, making a HOLD rating appropriate for now.
Bears say
Progyny is facing potential headwinds from economic uncertainty and competition from traditional health plan carriers and private tech-enabled health companies. Additionally, changes in government regulations could negatively impact their ability to provide fertility and family-building benefits. While the company has potential for growth with their Progyny Select offering and expanding into new markets, it is still too early to determine the impact on their pipeline for the year. It remains to be seen if the company can achieve its goals and overcome potential challenges in a changing healthcare landscape.
This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares